Search details
1.
Hereditary cancer testing in a diverse sample across three breast imaging centers.
Breast Cancer Res Treat
; 203(2): 365-372, 2024 Jan.
Article
in English
| MEDLINE | ID: mdl-37861889
2.
Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2.
Br J Cancer
; 128(12): 2283-2294, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37076566
3.
Suspected clonal hematopoiesis as a natural functional assay of TP53 germline variant pathogenicity.
Genet Med
; 24(3): 673-680, 2022 03.
Article
in English
| MEDLINE | ID: mdl-34906512
4.
Cross-sectional clinical cancer genomics community of practice survey analysis of provider attitudes and beliefs regarding the use of deceased family member tissue to guide living family member genetic cancer risk assessment.
J Genet Couns
; 31(5): 1164-1172, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35617031
5.
Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer.
Salud Publica Mex
; 64(1): 41-48, 2022 Feb 25.
Article
in English
| MEDLINE | ID: mdl-35438911
6.
Germline mutations and age at onset of lung adenocarcinoma.
Cancer
; 127(15): 2801-2806, 2021 08 01.
Article
in English
| MEDLINE | ID: mdl-33858029
7.
Multigene assessment of genetic risk for women for two or more breast cancers.
Breast Cancer Res Treat
; 188(3): 759-768, 2021 Aug.
Article
in English
| MEDLINE | ID: mdl-33826040
8.
Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 19(1): 77-102, 2021 01 06.
Article
in English
| MEDLINE | ID: mdl-33406487
9.
Rlip depletion prevents spontaneous neoplasia in TP53 null mice.
Proc Natl Acad Sci U S A
; 115(15): 3918-3923, 2018 04 10.
Article
in English
| MEDLINE | ID: mdl-29572430
10.
Suggested application of HER2+ breast tumor phenotype for germline TP53 variant classification within ACMG/AMP guidelines.
Hum Mutat
; 41(9): 1555-1562, 2020 09.
Article
in English
| MEDLINE | ID: mdl-32485079
11.
Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.
BMC Cancer
; 20(1): 1053, 2020 Nov 02.
Article
in English
| MEDLINE | ID: mdl-33138793
12.
Breastfeeding and the risk of epithelial ovarian cancer among women with a BRCA1 or BRCA2 mutation.
Gynecol Oncol
; 159(3): 820-826, 2020 12.
Article
in English
| MEDLINE | ID: mdl-33010967
13.
NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020.
J Natl Compr Canc Netw
; 18(4): 380-391, 2020 04.
Article
in English
| MEDLINE | ID: mdl-32259785
14.
BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry.
Hum Mutat
; 40(10): 1781-1796, 2019 10.
Article
in English
| MEDLINE | ID: mdl-31112363
15.
Li-Fraumeni syndrome: not a straightforward diagnosis anymore-the interpretation of pathogenic variants of low allele frequency and the differences between germline PVs, mosaicism, and clonal hematopoiesis.
Breast Cancer Res
; 21(1): 107, 2019 09 18.
Article
in English
| MEDLINE | ID: mdl-31533767
16.
Association between Clonal Hematopoiesis and Late Nonrelapse Mortality after Autologous Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant
; 25(12): 2517-2521, 2019 12.
Article
in English
| MEDLINE | ID: mdl-31445185
17.
Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Cancer
; 125(16): 2829-2836, 2019 08 15.
Article
in English
| MEDLINE | ID: mdl-31206626
18.
International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation.
Br J Cancer
; 121(1): 15-21, 2019 07.
Article
in English
| MEDLINE | ID: mdl-30971774
19.
Evaluation of ACMG-Guideline-Based Variant Classification of Cancer Susceptibility and Non-Cancer-Associated Genes in Families Affected by Breast Cancer.
Am J Hum Genet
; 98(5): 801-817, 2016 May 05.
Article
in English
| MEDLINE | ID: mdl-27153395
20.
Oophorectomy and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers.
Breast Cancer Res Treat
; 175(2): 443-449, 2019 Jun.
Article
in English
| MEDLINE | ID: mdl-30756284